- Home
- ERAS vs DAVE Comparison
ERAS vs DAVE Comparison
Compare ERAS & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | DAVE |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | DAVE |
|---|---|---|
| Price | $18.72 | $400.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $14.25 | ★ $312.75 |
| AVG Volume (30 Days) | ★ 5.5M | 605.1K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.28 |
| Revenue Next Year | N/A | $17.38 |
| P/E Ratio | ★ N/A | $17.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $152.21 |
| 52 Week High | $24.28 | $409.00 |
Technical Indicators
Market Signals| Indicator | ERAS | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 67.85 | 73.61 |
| Support Level | $12.36 | $231.19 |
| Resistance Level | $24.28 | N/A |
| Average True Range (ATR) | 1.20 | 22.85 |
| MACD | 0.22 | 3.22 |
| Stochastic Oscillator | 77.71 | 91.78 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, short-term liquidity, fee-free banking, and financial management tools, and finding side gigs.